<DOC>
	<DOCNO>NCT00655876</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Cetuximab may stop growth esophageal cancer block blood flow tumor . It yet know whether give paclitaxel cisplatin together radiation therapy effective without cetuximab treat esophageal cancer . PURPOSE : This randomized phase III trial compare well give paclitaxel cisplatin together radiation therapy work without cetuximab treat patient locally advanced esophageal cancer .</brief_summary>
	<brief_title>Paclitaxel , Cisplatin , Radiation Therapy With Without Cetuximab Treating Patients With Locally Advanced Esophageal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate whether addition cetuximab chemotherapy comprise paclitaxel , cisplatin , radiotherapy improve overall survival compare paclitaxel , cisplatin , radiotherapy alone patient esophageal cancer treat without surgery . Secondary - To evaluate whether addition cetuximab paclitaxel , cisplatin , radiotherapy improve local control increase clinical complete response decrease local recurrence patient . - To evaluate adverse event patient . - To evaluate endoscopic complete response rate patient . - To evaluate addition cetuximab paclitaxel , cisplatin , radiotherapy improves Esophageal Cancer Subscale score FACT-E quality life tool . - To evaluate quality-adjusted survival treatment arm use EQ-5D primary endpoint support primary hypothesis . OUTLINE : This multicenter study . Patients stratify accord histology ( adenocarcinoma* vs squamous ) , cancer lesion size ( &lt; 5 cm v ≥ 5 cm ) , disease status celiac node ( present v absent ) . Patients randomize 1 2 treatment arm . NOTE : * The adenocarcinoma stratum close 5/3/2012 . - Arm I : Patients receive cetuximab IV 1-2 hour , paclitaxel IV 1 hour , cisplatin IV 30-60 minute day 1 , 8 , 15 , 22 , 29 , 36 . Patients also undergo radiotherapy daily , 5 day week , 5½ week total dose 50.4Gy . - Arm II : Patients receive paclitaxel cisplatin arm I . Patients also undergo radiotherapy arm I . Patients undergo endoscopy 6 8 week completion chemoradiotherapy . Quality life assess baseline , within 1 week post-treatment endoscopy , 1 2 year begin study treatment . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary squamous cell adenocarcinoma* esophagus gastroesophageal junction Patients involvement gastroesophageal junction Siewert type I II tumor ( tumor arise distal esophagus involve esophagogastric junction tumor start esophagogastric junction involve cardia ) eligible Patients cervical esophageal carcinoma eligible Patients celiac , perigastric , mediastinal , supraclavicular adenopathy eligible NOTE : * The adenocarcinoma stratum close 5/3/2012 . Stage T1 , N1 , M0 ; T24 , Any N , M0 ; Any T , Any N , M1a disease base history/physical examination , endoscopy biopsy , AND PET/PETCT scan chest/abdominal CT scan within 6 week prior registration Disease must encompass radiotherapy field No evidence tracheoesophageal fistula invasion trachea major bronchus Patients T34 proximal thoracic esophageal tumor ( 1525 cm ) must undergo bronchoscopy exclude fistula PATIENT CHARACTERISTICS : Zubrod performance status 02 ANC ≥ 1,500/mm³ Platelets ≥ 100,000 cells/mm³ Hemoglobin ≥ 8.0 g/dL ( transfusion intervention achieve Hgb ≥ 8.0 g/dL allow ) Creatinine ≤ 1.5 mg/dL Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 3 time ULN Negative pregnancy test Not pregnant nursing Fertile patient must use effective contraception Total intake ( oral/enteral ) must ≥ 1,500 kCal/day No prior invasive malignancy except nonmelanomatous skin cancer ( e.g. , carcinoma situ breast , oral cavity , cervix ) unless diseasefree ≥ 2 year No prior allergic reaction study drug No prior severe infusion reaction monoclonal antibody No severe , active comorbidity , include follow : Unstable angina and/or congestive heart failure require hospitalization within past 3 month Transmural myocardial infarction within past 6 month Acute bacterial fungal infection require intravenous antibiotic Chronic obstructive pulmonary disease exacerbation respiratory illness require hospitalization preclude study therapy Acquired immune deficiency syndrome base upon current CDC definition HIV testing require entry study PRIOR CONCURRENT THERAPY : No prior systemic chemotherapy esophageal cancer ( prior chemotherapy another cancer allow ) No prior therapy specifically directly target EGFR pathway No prior platinumbased and/or paclitaxelbased therapy No prior radiotherapy would result overlap plan study radiotherapy field No concurrent investigational agent No concurrent cytotoxic agent No concurrent radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>stage IIA esophageal cancer</keyword>
	<keyword>stage IIB esophageal cancer</keyword>
	<keyword>stage IIIA esophageal cancer</keyword>
	<keyword>stage IIIB esophageal cancer</keyword>
	<keyword>stage IIIC esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
</DOC>